U
UpDoc
AI-driven platform enhancing chronic disease management through remote patient monitoring and conversational AI
About UpDoc
UpDoc.ai is a pioneering healthcare startup focused on improving outcomes and reducing costs for millions of Americans suffering from chronic diseases. The company operates in the healthcare technology market, specifically targeting patients who lack access to consistent medical care. UpDoc.ai leverages a unique model called RPI (Remote Patient Intelligence), which was developed by practicing physicians and academic leaders from Stanford University.
The core of UpDoc.ai's service is its AI-driven platform that uses remote patient monitoring (RPM) and other data to deliver clinical care. This platform is designed to manage chronic diseases more effectively and efficiently than traditional methods. One of the standout features of UpDoc.ai's technology is its ability to manage medication prescriptions through conversational AI, a first in clinical trials.
UpDoc.ai primarily serves patients with chronic conditions, healthcare providers, and potentially insurance companies looking to reduce healthcare costs. The business model revolves around providing a subscription-based service to healthcare providers and institutions, who in turn use the platform to monitor and manage their patients remotely. This model not only helps in improving patient outcomes but also significantly reduces the labor-intensive aspects of traditional healthcare delivery.
Revenue is generated through subscription fees from healthcare providers and possibly through partnerships with insurance companies and other healthcare stakeholders. By offering a cost-effective and clinically validated solution, UpDoc.ai aims to become a key player in the healthcare technology market.
Source: Dealroom company dataKnowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEED✓Equity / VC | Jun 2026 | $18M | $72M | Mayo Clinic · Oxeon · Section 32 · Cathay Innovation | ↗ |
| SEED✓Equity / VC | Jan 2024 | $0 | — | Mayo Clinic · Oxeon Partners · Polaris Partners · Eli Lilly | ↗ |
Growth signals
Latest recorded traffic for UpDoc is 7.2K monthly website visits, up 105.7% over the last three months. UpDoc's team grew 90% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed9 investors entered at this stage
Polaris Partners
Mayo Clinic
Oxeon Partners
Eli Lilly
Oxeon
Section 32
Cathay Innovation
Pear Ventures
American Diabetes Association
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about UpDoc on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See UpDoc’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







